MacDougall Creative 6/1/22 MacDougall Creative 6/1/22

OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer

MacDougall Creative 5/10/22 MacDougall Creative 5/10/22

OncoNano Medicine Announces the Appointment of Elina Lavit as Vice President, Business Development

MacDougall Creative 4/13/22 MacDougall Creative 4/13/22

OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting

MacDougall Creative 4/12/22 MacDougall Creative 4/12/22

OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD Platform at AACR 2022 Annual Meeting

MacDougall Creative 3/11/22 MacDougall Creative 3/11/22

OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

MacDougall Creative 12/17/21 MacDougall Creative 12/17/21

OncoNano Medicine Appoints Brett Giroir, M.D., to Board of Directors

MacDougall Creative 10/25/21 MacDougall Creative 10/25/21

$18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas

MacDougall Creative 10/14/21 MacDougall Creative 10/14/21

Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study

MacDougall Creative 10/8/21 MacDougall Creative 10/8/21

Positive Preclinical Data for ONM-501 at AACR Virtual Conference

MacDougall Creative 9/30/21 MacDougall Creative 9/30/21

Present at The American Association for Cancer Research Virtual Conference

MacDougall Creative 9/22/21 MacDougall Creative 9/22/21

Expanded Research Collaboration with UT Southwestern Medical Center

MacDougall Creative 9/20/21 MacDougall Creative 9/20/21

OncoNano Medicine to Present at The World Molecular Imaging Congress

MacDougall Creative 7/19/21 MacDougall Creative 7/19/21

OncoNano Medicine to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium

MacDougall Creative 6/17/21 MacDougall Creative 6/17/21

OncoNano Medicine Raises ~$50 Million in Series B Financing

MacDougall Creative 3/31/21 MacDougall Creative 3/31/21

OncoNano Awarded $15.4 Million Grant

MacDougall Creative 3/31/21 MacDougall Creative 3/31/21

Publication of ONM-100 Phase 1

MacDougall Creative 2/10/21 MacDougall Creative 2/10/21

Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer

MacDougall Creative 2/9/21 MacDougall Creative 2/9/21

Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer

MacDougall Creative 11/9/20 MacDougall Creative 11/9/20

OncoNano Announces Positive Preclinical Data for ONM-400 Tumor Specific IL-2 Delivery at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

MacDougall Creative 10/7/20 MacDougall Creative 10/7/20

OncoNano Announces Positive Clinical Data for Cancer Imaging Agent ONM-100 at The World Molecular Imaging Congress

Press Releases